Another study found that lenvatinib prevents nuclear translocation of β-catenin to inhibit the expression of GPX2, thereby increasing the levels of ROS in HCC cells and furthering cancer cell apoptosis [52]. The gene discussed is GPX2; the disease is hepatocellular carcinoma.